{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:05:20Z","timestamp":1791266720543,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41409-025-02554-w","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T15:34:31Z","timestamp":1743521671000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4553-3065","authenticated-orcid":false,"given":"David","family":"Michonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-465X","authenticated-orcid":false,"given":"Sophie","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-2742","authenticated-orcid":false,"given":"Maud","family":"D\u2019Aveni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-8106","authenticated-orcid":false,"given":"Jean Jacques","family":"Tudesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Villate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-7920","authenticated-orcid":false,"given":"Ambroise","family":"Mar\u00e7ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Raus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2554_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","volume":"59","author":"JR Passweg","year":"2024","unstructured":"Passweg JR, Baldomero H, Ciceri F, de la C\u00e1mara R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transpl. 2024;59:803\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"2554_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng G-S, et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"2554_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/asheducation-2015.1.225","volume":"2015","author":"RS Negrin","year":"2015","unstructured":"Negrin RS. Graft-versus-host disease versus graft-versus-leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:225\u201330.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2554_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","volume":"39","author":"GR Hill","year":"2021","unstructured":"Hill GR, Betts BC, Tkachev V, Kean LS, Blazar BR. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021;39:19\u201349.","journal-title":"Annu Rev Immunol"},{"key":"2554_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1079708","volume":"13","author":"G Socie","year":"2022","unstructured":"Socie G, Michonneau D. Milestones in acute GVHD pathophysiology. Front Immunol. 2022;13:1079708.","journal-title":"Front Immunol"},{"key":"2554_CR6","doi-asserted-by":"publisher","unstructured":"Langer R, Lelas A, Rittenschober M, Piekarska A, Sadowska-Klasa A, Sabol I et al. Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease\u2014an analysis from transplant centers across Europe. Front Transplant. 2024;3. https:\/\/doi.org\/10.3389\/frtra.2024.1332181.","DOI":"10.3389\/frtra.2024.1332181"},{"key":"2554_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther. 2021;27:545\u201357.","journal-title":"Transpl Cell Ther"},{"key":"2554_CR8","doi-asserted-by":"publisher","first-page":"504.e1","DOI":"10.1016\/j.jtct.2020.12.027","volume":"27","author":"CR Bachier","year":"2021","unstructured":"Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, et al. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis. Transplant Cell Ther. 2021;27:504.e1\u2013504.e6.","journal-title":"Transplant Cell Ther"},{"key":"2554_CR9","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N. Engl J Med. 2017;377:2565\u201379.","journal-title":"N. Engl J Med"},{"key":"2554_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI41072","volume":"120","author":"K Matsuoka","year":"2010","unstructured":"Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479\u201393.","journal-title":"J Clin Invest"},{"key":"2554_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix HT, Pohlreich D, Kouba M, K\u00f6rm\u00f6czi U, Lohmann I, Feldmann K, et al. Elevated Numbers of Immature\/Transitional CD21\u2212 B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2008;14:208\u201319.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2554_CR12","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","volume":"113","author":"S Sarantopoulos","year":"2009","unstructured":"Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113:3865\u201374.","journal-title":"Blood"},{"key":"2554_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169732","volume":"8","author":"JC Poe","year":"2023","unstructured":"Poe JC, Fang J, Zhang D, Lee MR, DiCioccio RA, Su H, et al. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight. 2023;8:e169732.","journal-title":"JCI Insight"},{"key":"2554_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180331","volume":"134","author":"J Bordenave","year":"2024","unstructured":"Bordenave J, Gajda D, Michonneau D, Vallet N, Chevalier M, Clappier E, et al. Deciphering bone marrow engraftment after allogeneic stem cell transplantation in humans using single-cell analyses. J Clin Invest. 2024;134:e180331.","journal-title":"J Clin Invest"},{"key":"2554_CR15","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","volume":"123","author":"R Flynn","year":"2014","unstructured":"Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123:3988\u201398.","journal-title":"Blood"},{"key":"2554_CR16","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","volume":"127","author":"E Forcade","year":"2016","unstructured":"Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016;127:2489\u201397.","journal-title":"Blood"},{"key":"2554_CR17","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1172\/JCI75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124:4266\u201380.","journal-title":"J Clin Invest"},{"key":"2554_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","volume":"116","author":"GR Hill","year":"2010","unstructured":"Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116:819\u201328.","journal-title":"Blood"},{"key":"2554_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144\u201354.","journal-title":"Blood"},{"key":"2554_CR20","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u2013e159.","journal-title":"Lancet Haematol"},{"key":"2554_CR21","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1182\/bloodadvances.2021005286","volume":"5","author":"J Pidala","year":"2021","unstructured":"Pidala J, Onstad L, Martin PJ, Hamilton BK, Cutler C, Kitko CL, et al. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Adv. 2021;5:4549\u201359.","journal-title":"Blood Adv"},{"key":"2554_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3324\/haematol.2021.279814","volume":"108","author":"GL Chen","year":"2023","unstructured":"Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, et al. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica. 2023;108:483\u20139.","journal-title":"Haematologica"},{"key":"2554_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385:228\u201338.","journal-title":"N Engl J Med"},{"key":"2554_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024;391:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2554_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov A, Blazar BR. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol. 2021;230:108823.","journal-title":"Clin Immunol"},{"key":"2554_CR26","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278\u201389.","journal-title":"Blood"},{"key":"2554_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021;39:1888\u201398.","journal-title":"J Clin Oncol"},{"key":"2554_CR28","doi-asserted-by":"publisher","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","volume":"6","author":"Z DeFilipp","year":"2022","unstructured":"DeFilipp Z, Kim HT, Yang Z, Noonan J, Blazar BR, Lee SJ, et al. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. Blood Adv. 2022;6:6263\u201370.","journal-title":"Blood Adv"},{"key":"2554_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2554_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2554_CR31","unstructured":"R: The R Project for Statiscal Computing. 2023. Available from: https:\/\/www.r-project.org\/."},{"key":"2554_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/bmt.2015.195","volume":"51","author":"C Fiuza-Luces","year":"2016","unstructured":"Fiuza-Luces C, Simpson RJ, Ram\u00edrez M, Lucia A, Berger NA. Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transpl. 2016;51:13\u201326.","journal-title":"Bone Marrow Transpl"},{"key":"2554_CR33","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.bbmt.2018.03.008","volume":"24","author":"FF Yalniz","year":"2018","unstructured":"Yalniz FF, Murad MH, Lee SJ, Pavletic SZ, Khera N, Shah ND, et al. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biol Blood Marrow Transpl. 2018;24:1920\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2554_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41409-023-01930-8","volume":"58","author":"D Michonneau","year":"2023","unstructured":"Michonneau D, Quignot N, Jiang H, Reichenbach D, Kelly M, Burrell A, et al. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France. Bone Marrow Transpl. 2023;58:514\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2554_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/1744666X.2023.2152330","volume":"19","author":"A Salhotra","year":"2023","unstructured":"Salhotra A, Sandhu K, O\u2019Hearn J, Ali H, Nakamura R, Modi BG. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. Expert Rev Clin Immunol. 2023;19:241\u201351.","journal-title":"Expert Rev Clin Immunol"},{"key":"2554_CR36","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","volume":"27","author":"DJ Martini","year":"2022","unstructured":"Martini DJ, Chen Y-B, DeFilipp Z. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. Oncologist. 2022;27:685\u201393.","journal-title":"Oncologist"},{"key":"2554_CR37","doi-asserted-by":"publisher","unstructured":"Heidenreich S, Egger-Heidrich K, Halter JP, Jost L, St\u00f6lzel F, Perl M et al. Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis. Bone Marrow Transplant. 2025. https:\/\/doi.org\/10.1038\/s41409-024-02507-9.","DOI":"10.1038\/s41409-024-02507-9"},{"key":"2554_CR38","doi-asserted-by":"publisher","first-page":"700.e1","DOI":"10.1016\/j.jtct.2022.06.020","volume":"28","author":"SJ Lee","year":"2022","unstructured":"Lee SJ, Cutler C, Blazar BR, Tu A, Yang Z, Pavletic SZ. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. Transplant Cell Ther. 2022;28:700.e1\u2013700.e6.","journal-title":"Transplant Cell Ther"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02554-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:18:31Z","timestamp":1749543511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02554-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02554-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5912613\/v1","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DM received research grants from Novartis, Sanofi and CSL Behring, consulting fees from Novartis, Incyte, Sanofi, Jazz Pharmaceuticals, and Mallinckrodt. FM received honoraria from Therakos\/Mallinckrodt, Janssen, Biocodex, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, Priothera, and Astellas. EF received speaker fees and honoraria for advisory board from Novartis, Sanofi, Gilead, Alexion, MSD, Astellas, Jazz, Pfizer, GSK and Sobi. ML received research grant from Janssen, consulting honoraria from Abbvie, Alexion, Bristol Myers Squibb, Gilead, Glaxo Smith Kline, Incyte, Jazz, Kartos, Mallinkrodt, Novartis, Roche, Sanofi, Takeda. Other authors did not declare any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}